Search - tctmd.com

Displaying 241 - 260 of 457

Sort: Relevancy | Date

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE Randomized Clinical Trial

Presentation EuroPCR 2017

The ARTE Randomized Clinical Trial

Presenter: Josep Rodés-Cabau

May 17, 2017

Presentation EuroPCR 2017

ABSORB Japan Results: 3-year Clinical and Angiographic Results

Presenter: Ken Kozuma

May 17, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

Presentation EuroPCR 2017

Final five-year Clinical and Echocardiographic Results of Treatment for Severe Aortic Stenosis with a Self-Expanding Bioprosthesis from the ADVANCE Study

Presenter: Ulrich Gerckens

May 17, 2017

News Conference News EuroPCR 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

Shelley Wood

May 17, 2017

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

Presentation EuroPCR 2017

A Prospective, Randomised Investigation of a Novel Transcatheter Aortic Valve Implantation System: The REPRISE III Trial

Presenter: Ted E. Feldman

May 16, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Conference News EuroPCR 2017

iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows

Caitlin E. Cox

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Conference News EuroPCR 2016

‘Europe Isn’t Waiting’: MitraClip Moves Into New Niches, Big and Small

Shelley Wood

May 26, 2016

News Conference News EuroPCR 2016

Sex Disparities in MI Care Are Narrowing, but There’s Still a Long Way to Go

Caitlin E. Cox

May 25, 2016

News Conference News EuroPCR 2016

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Michael O'Riordan

May 23, 2016

Presentation EuroPCR 2016

Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation

Presenter: Bernando Cortese

May 23, 2016

Advertisement

The ARTE Randomized Clinical Trial

ABSORB Japan Results: 3-year Clinical and Angiographic Results

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Final five-year Clinical and Echocardiographic Results of Treatment for Severe Aortic Stenosis with a Self-Expanding Bioprosthesis from the ADVANCE Study

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

A Prospective, Randomised Investigation of a Novel Transcatheter Aortic Valve Implantation System: The REPRISE III Trial

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

iFR and FFR Equally Safe for Deferring Revascularization, Pooled Analysis Shows

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

‘Europe Isn’t Waiting’: MitraClip Moves Into New Niches, Big and Small

Sex Disparities in MI Care Are Narrowing, but There’s Still a Long Way to Go

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content